Carboplatin plus paclitaxel improves quality of life in ovarian cancer
the ONA take:
There is no significant quality of life advantage of cisplatin plus topotecan compared with paclitaxel plus carboplatin in the treatment of women with newly diagnosed ovarian cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
A recent phase 3 study in women with newly diagnosed stage 2B or greater ovarian cancer found that cisplatin plus topotecan followed by carboplatin plus paclitaxel had a significantly lower response rate vs paclitaxel plus carboplatin. The study also demonstrated no significant difference in progression-free survival at 43 months of follow-up.
In this analysis, researchers sought to evaluate the impact of each regimen on quality of life. Results showed that global quality of life, physical symptoms, fatigue, and various function scores significantly improved in both groups, but there was no significant difference between the arms. Researchers found that nausea and vomiting improve more with paclitaxel plus carboplatin during and after treatment.
The findings of this analysis combined with the efficacy results of the phase 3 trial suggest that carboplatin plus paclitaxel should continue to be the standard of care for patients with newly diagnosed ovarian cancer.
There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|